Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).